Anoro Ellipta (Umeclidinium and Vilanterol) – COPD | HongKong DengYue Medicine

Anoro Ellipta Application Scope

Anoro Ellipta is a once-daily inhalation powder combining umeclidinium (a long-acting muscarinic antagonist) and vilanterol (a long-acting beta2-agonist). It is used to improve airflow and reduce symptoms in the maintenance treatment of chronic obstructive pulmonary disease (COPD).

Characteristics

• Ingredients: Umeclidinium and Vilanterol

• Properties:

  • Anoro Ellipta is a combination of an anticholinergic (umeclidinium) and a long-acting beta2-adrenergic agonist (vilanterol).

  • It functions as a bronchodilator, relaxing airway muscles to improve breathing in COPD patients.

• Packaging Specification:

  • Available as a dry powder inhaler (Ellipta device) containing:

    • 7 doses

    • 30 doses

    • Multipacks of 90 doses (3 inhalers of 30 doses each)

  • Each inhaler includes a dose counter and is packaged in a foil laminate tray with a desiccant to protect from moisture.

• Storage:

  • Store at room temperature between 68°F to 77°F (20°C to 25°C).

  • Keep the inhaler inside its sealed tray until first use to protect from moisture.

  • Once opened, use within 6 weeks.

• Expiry Date: The expiry date is indicated on the carton, tray, and inhaler labeled as ‘EXP’.

• Executive Standard: Approved by the U.S. Food and Drug Administration (FDA) in 2013.

• Approval Number:

  National Drug Code (NDC):

  • 0173-0869-10 (30 inhalations)

  • 0173-0869-06 (14 inhalations)

• Date of Revision: June 2023.

• Manufacturer:

  • GlaxoSmithKline LLC

  • Research Triangle Park, NC 27709, USA

Guidelines for the Use of Anoro Ellipta

• Dosage and Administration:

  • Recommended dose: One inhalation (62.5 mcg umeclidinium / 25 mcg vilanterol) once daily.

  • Administer at the same time each day.

  • For oral inhalation only.

  • Do not use more than once every 24 hours.

• Adverse Reactions:

  Common side effects (≥1% incidence):

  • Pharyngitis

  • Sinusitis

  • Lower respiratory tract infection

  • Constipation

  • Diarrhea

  • Pain in the extremity

  • Muscle spasms

  • Neck pain

  • Chest pain

• Contraindications:

  • Severe hypersensitivity to milk proteins or any component of the product.

  • Use of a LABA without an inhaled corticosteroid in patients with asthma.

• Precautions:

  • Not for the relief of acute bronchospasm or the treatment of asthma.

  • Use with caution in patients with:

    • • Cardiovascular disorders

      • Convulsive disorders

      • Thyrotoxicosis

      • Diabetes mellitus

      • Narrow-angle glaucoma

      • Urinary retention

Anoro Ellipta Interactions

• Drug Interactions:

  Use with caution when co-administered with:

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir)

  • Monoamine oxidase inhibitors and tricyclic antidepressants

  • Beta-blockers

  • Diuretics

  • Other anticholinergic-containing drugs

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.